Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Midazolam 5 mg/ml Solution for injection or infusion
Medicines register · Ireland

Midazolam 5 mg/ml Solution for injection or infusion

Authorisation PA2315/063/006 · Accord Healthcare Ireland Ltd.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Accord Healthcare Ireland Ltd. (all products →)
Active substance
Midazolam
Clinical trials
74 clinical trials →
Dosage form
Solution for injection/infusion
Routes of administration
Intramuscular use, Intravenous use
ATC codes
N05CD, N05CD08
First authorised
01/09/2006
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Generic application (Article 10(1) of Directive No 2001/83/EC)

Midazolam: supply and approvals

29 authorised products on the HPRA list contain Midazolam. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
Buccolam: Shortage resolved, first published 25 Apr 2014
US shortage (FDA)
Midazolam Hydrochloride Injection: in shortage, updated 18 Nov 2026
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 20 years (since 1 September 2006). The HPRA list marks it as marketed in Ireland.

Other medicines with Midazolam in Ireland

22 other products on the HPRA list contain Midazolam, from 7 licence holders; 10 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Midazolam 1 mg/ml Solution for Injection or InfusionAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Midazolam 1 mg/ml solution for injection in pre-filled syringeLaboratoire AguettantNational authorisation (PA)Marketed
Midazolam 1 mg/ml solution for injection/infusionLaboratoire AguettantNational authorisation (PA)Marketed
Midazolam 2 mg/ml Solution for injection or infusionAccord Healthcare Ireland Ltd.National authorisation (PA)Marketed
Midazolam 5 mg/ml solution for injection/infusionLaboratoire AguettantNational authorisation (PA)Marketed
Midazolam Rowa 10 mg oromucosal solutionRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Midazolam Rowa 2.5 mg oromucosal solutionRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Midazolam Rowa 5 mg oromucosal solutionRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Midazolam Rowa 7.5 mg oromucosal solutionRowa Pharmaceuticals Limited,National authorisation (PA)Marketed
Ozalin 2 mg/ml oral solution in single-dose containerIstituto Gentili S.r.l.National authorisation (PA)Marketed
BUCCOLAM 10 mg oromucosal solutionLaboratorios Lesvi, S.L.Centralised EU authorisationNot stated
BUCCOLAM 2.5 mg oromucosal solutionLaboratorios Lesvi, S.L.Centralised EU authorisationNot stated

All 23 products with Midazolam →

Other substances in ATC group N05CD

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 6 other active substances share the group N05CD with this product:

Flurazepam (2) · Triazolam (2) · Midazolam hydrochloride (2) · Temazepam (2) · Remimazolam besilate (1) · Remimazolam (in house) (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Accord Healthcare Ireland Ltd. holds 235 products on the HPRA list, with 112 different active substances; 137 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.